Please login to the form below

Not currently logged in
Email:
Password:

Amarin

This page shows the latest Amarin news and features for those working in and with pharma, biotech and healthcare.

The Midas Touch

The Midas Touch

Then along comes Amarin. By investing in the isolation of a single compound from the soup that is fish-oil, they have developed a product called Vascepa. ... Well done Amarin. The practical lesson of Amarin’s Vascepa for the rest of us is hidden in

Latest news

  • Amarin hits jackpot with astonishing heart benefits from fish oil product Amarin hits jackpot with astonishing heart benefits from fish oil product

    Amarin CEO John Thero. “We are delighted with these topline study results,” said John Thero, president and CEO of Amarin. ... of LDL-C control with standard of care statin therapy in studied patients,” added Craig Granowitz, MD, PhD, senior vice

  • Amarin sues FDA over off-label policy Amarin sues FDA over off-label policy

    Claims block on discussing off-label uses conflicts freedom of speech. Irish pharma company Amarin Corp is suing the FDA, claiming that a block on discussing off-label uses for drugs ... Amarin is in the process of carrying out a cardiovascular outcomes

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Aside from GSK, the launch of a lower-priced Lovaza generic in the US also impacts Amarin Pharmaceuticals' Vascepa (icosapent ethyl), another fish oil-based therapy that is already on the

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    Advisory committee wants more data on Vascepa. Shares in Irish company Amarin Corp nosedived yesterday after a US Food and Drug Administration (FDA) advisory committee voted against approval of its fish ... Meanwhile, the cost of running REDUCE-IT is

  • Senior changes for Forest and Amarin

    Dr Lawrence S Olanoff is to retire as president of Forest Laboraties, while Joseph S Zakrzewski is to become CEO of Amarin Corporation. ... for only a few months before resigning. Amarin announced his appointment in August of this year.

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Teva's Mark Salyer joins Amarin Teva's Mark Salyer joins Amarin

    Takes up newly-created chief commercial officer role. Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer. ... Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics